7 drug(s) with this reaction
18,736 total reports
Maternal Exposure During Pregnancy has been reported as an adverse reaction across 7 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 18,736 adverse event reports mention maternal exposure during pregnancy in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with maternal exposure during pregnancy, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have maternal exposure during pregnancy listed in their FDA adverse event reports, sorted by report count:
In addition to maternal exposure during pregnancy, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
7 drug(s) manufactured by Abbvie Inc have maternal exposure during pregnancy listed in their FDA adverse event reports: Humira, ADALIMUMAB, RITONAVIR, RISANKIZUMAB-RZAA, LOPINAVIR AND RITONAVIR, and others.
There are a combined 18,736 reports of maternal exposure during pregnancy across 7 Abbvie Inc drug(s) in the FDA adverse event database.